Equillium, Inc. (NASDAQ:EQ) Short Interest Update

Equillium, Inc. (NASDAQ:EQ) saw a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 93,300 shares, a growth of 245.6% from the January 15th total of 27,000 shares. Based on an average trading volume of 771,800 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.5% of the company’s shares are short sold.

Institutional Investors Weigh In On Equillium

An institutional investor recently raised its position in Equillium stock. DCF Advisers LLC grew its holdings in Equillium, Inc. (NASDAQ:EQ) by 91.0% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 62,947 shares of the company’s stock after buying an additional 29,985 shares during the quarter. DCF Advisers LLC owned approximately 0.18% of Equillium worth $47,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 27.05% of the company’s stock.

Equillium Stock Performance

NASDAQ:EQ opened at $0.94 on Friday. Equillium has a fifty-two week low of $0.49 and a fifty-two week high of $3.25. The firm has a market cap of $33.30 million, a PE ratio of -6.71 and a beta of 1.79. The business has a 50 day moving average price of $0.71 and a 200-day moving average price of $0.81.

Equillium Company Profile

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.